Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Core Insights - Argenx SE's stock is experiencing upward momentum following the release of positive topline data from the Phase 3 ADAPT SERON study of Vyvgart, which met its primary endpoint for AChR-Ab seronegative gMG patients [1] Group 1: Clinical Data and Regulatory Plans - The ADAPT SERON study demonstrated a statistically significant improvement in MG-ADL total score for patients treated with Vyvgart compared to placebo [1] - Argenx plans to submit a supplemental marketing application to the FDA by the end of 2025 to expand Vyvgart's label to include adult AChR-Ab seronegative gMG patients across all three subtypes [2] - Positive clinical data from the ADAPT SERON trial suggest that FcRN inhibition may effectively reduce disease progression in seronegative gMG patients [3] Group 2: Market Potential and Financial Projections - Analyst Myles Minter from William Blair indicates that the strong trial results support the potential of FcRN inhibition across IgG-driven diseases, reinforcing a bullish outlook on Argenx [4] - The anticipated approval for Vyvgart in seronegative gMG could expand the estimated total addressable market (TAM) by 18% by 2030, with projected sales of $2.93 billion in 2025, reflecting a 39% year-over-year increase [4] - Additional indications from ongoing studies could further enhance Vyvgart's market, with data from the ADAPT-OCULAR study expected in the first half of 2026, potentially adding another 12% to the market [5] Group 3: Analyst Ratings and Stock Performance - William Blair reiterated an Outperform rating for Argenx, while Piper Sandler raised its price target from $750 to $820, maintaining an Overweight rating [6] - As of the latest check, Argenx's stock is trading higher by 3.18% at $698.83 [6]